Rcnet 50 mg contains sunitinib, a targeted cancer therapy used to treat several types of advanced or metastatic cancers. It is an oral medication that belongs to the class of tyrosine kinase inhibitors. Sunitinib works by interfering with cancer cell growth and cutting off the blood supply that tumors need to thrive.

Sunitinib is commonly used when conventional treatments may not be suitable or have failed. Because of its targeted approach, it offers a more specific way to block cancer progression compared to traditional chemotherapy.

Sunitinib works by blocking multiple tyrosine kinase receptors, which are involved in the growth and spread of cancer cells. These include receptors for:

• Vascular endothelial growth factor (VEGF)

• Platelet-derived growth factor (PDGF)

• Stem cell factor receptor (c-KIT)

• Other related pathways

  Uses

  Rcnet (sunitinib) is approved for use in the treatment of the following cancers:

  • Renal cell carcinoma, a common form of kidney cancer, especially in advanced stages

  • Gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib

  • Pancreatic neuroendocrine tumors, particularly when the disease is advanced and not suitable for surgery

    Adverse Effects

    While Rcnet offers a targeted approach, it may cause a range of side effects. Some are manageable with supportive care, while others may require dose adjustments.

    Common Side Effects

    • Tiredness or fatigue

    • High blood pressure

    • Diarrhea

    • Nausea or loss of appetite

    • Skin discoloration or hand-foot syndrome (pain or redness on palms and soles)

    • Mouth sores

    • Hair color changes